华海清科(688120) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 reached ¥912,498,331.19, representing a 34.14% increase compared to ¥680,248,921.74 in the same period last year[4] - Net profit attributable to shareholders was ¥233,417,322.55, up 15.47% from ¥202,145,758.93 year-on-year[4] - The basic earnings per share increased to ¥0.99, a rise of 16.47% from ¥0.85 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥912.50 million, a 34.1% increase from ¥680.25 million in Q1 2024[18] - Net profit for Q1 2025 was ¥233.42 million, representing a 15.4% increase compared to ¥202.15 million in Q1 2024[19] - Basic earnings per share for Q1 2025 were ¥0.99, compared to ¥0.85 in Q1 2024, reflecting a 16.5% increase[19] - The company reported a total profit of ¥259.99 million for Q1 2025, up from ¥230.06 million in Q1 2024, marking a 12.9% increase[19] Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 92.31%, amounting to ¥12,916,712.88, compared to ¥167,902,222.64 in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥12.92 million, down 92.3% from ¥167.90 million in Q1 2024[20] - Cash flow from investing activities for Q1 2025 showed a net outflow of ¥335.29 million, compared to a net outflow of ¥87.58 million in Q1 2024[21] - Cash and cash equivalents at the end of Q1 2025 totaled ¥2.32 billion, a decrease from ¥2.48 billion at the end of Q1 2024[21] - The company's current assets totaled RMB 8,611,633,309.82, down from RMB 8,832,012,584.58 at the end of 2024, primarily due to a decrease in cash and cash equivalents[13][15] - The company's cash and cash equivalents decreased to RMB 2,373,573,585.01 from RMB 2,761,029,293.79, a decline of approximately 14.1%[13] Research and Development - Research and development (R&D) expenses totaled ¥107,255,256.76, reflecting a 33.33% increase from ¥80,440,446.19, with R&D expenses accounting for 11.75% of operating revenue[5] - Research and development expenses for Q1 2025 were ¥109.44 million, an increase of 41.2% from ¥77.44 million in Q1 2024[18] - The company plans to continue increasing R&D investment to enhance product development and market competitiveness[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,666,230,019.71, a slight decrease of 0.72% from ¥11,750,821,583.13 at the end of the previous year[5] - The company's total assets amounted to RMB 11,666,230,019.71, a slight decrease from RMB 11,750,821,583.13 as of December 31, 2024[13][15] - The company's inventory increased to RMB 3,487,586,141.11 from RMB 3,267,533,611.78, indicating a growth of approximately 6.7%[13][15] - The total liabilities decreased to RMB 4,938,417,261.83 from RMB 5,270,511,451.80, reflecting a reduction of about 6.3%[15] - The company's equity attributable to shareholders rose to RMB 6,727,812,757.88 from RMB 6,473,073,313.93, marking an increase of approximately 3.9%[15] - The company's short-term borrowings decreased to RMB 24,549,992.35 from RMB 27,501,155.54, a decline of about 7.1%[15] - The accounts receivable increased to RMB 698,094,219.91 from RMB 663,535,781.06, representing a growth of approximately 5.2%[13] - The company's long-term equity investments increased to RMB 248,617,490.64 from RMB 223,649,216.82, showing an increase of about 11.2%[14] - The company reported a significant increase in other non-current financial assets to RMB 61,004,432.40 from RMB 43,850,566.27, reflecting a growth of about 39.1%[14] Market Performance - The company has seen a significant increase in market share and sales scale for CMP products, contributing to the revenue growth[8] - The company reported a decrease in other comprehensive income, with a net amount of -¥705,840.99 in Q1 2025 compared to -¥756,947.28 in Q1 2024[19]